AbbVie records a $3.5 billion impairment charge following the failure of emraclidine in Phase II schizophrenia trials.

US biopharma Biohaven and Dutch biotech Merus have announced a research collaboration and license agreement to co-develop ...

City Therapeutics partners with Bausch + Lomb to develop an RNAi-based therapy for geographic atrophy, leveraging City’s RNAi ...

Gilead Sciences and Danish dermatology specialist LEO Pharma announced a strategic partnership, marking another move outside ...

Teva partners with Klinge Biopharma and Formycon to commercialize FYB203, an Eylea biosimilar, as Ahzantive in Europe and ...

New export figures for November from Statistics Denmark show that medicine constitutes a significant part of total Danish ...

A clinical-stage biopharma company focused on developing therapies for obesity and other cardiometabolic disorders.

China’s National Medical Products Administration (NMPA) has approved French Pharma major Sanofi’s Sarclisa (isatuximab), an anti-CD38 medicine, in combination with pomalidomide and dexamethasone (Pd) ...

One of the most promising areas of medical innovation in the next five years is immuno-oncology (I-O)/cancer therapeutics ...

US biotech Capricor Therapeutics today announced the completion of the submission of its Biologics License Application (BLA) ...

Full mergers and acquisitions in the pharmaceutical and biotechnology in 2024 fluctuated throughout the year with hardly any in some months and a significant number in other. But one thing was clear – ...

Japanese drugmaker Chugai Pharmaceuticals has obtained regulatory approval from the Ministry of Health, Labor and Welfare (MHLW) for Lunsumio (mosunetuzumab) for intravenous infusion 1mg and 30mg for ...